PT  - JOURNAL ARTICLE
AU  - Yarema, Roman
AU  - Volodko, Nataliya
AU  - Petronchak, Orest
AU  - Huley, Roman
AU  - Ohorchak, Myron
AU  - Mylyan, Yuriy
TI  - 1298 Evaluation of the peritoneal surface disease severity score (PSDSS) in ovarian cancer patients undergoing cytoreductive surgery and HIPEC: two pathogenetic types based study
AID  - 10.1136/ijgc-2024-ESGO.826
DP  - 2024 Mar 01
TA  - International Journal of Gynecologic Cancer
PG  - A421--A422
VI  - 34
IP  - Suppl 1
4099  - http://ijgc.bmj.com/content/34/Suppl_1/A421.2.short
4100  - http://ijgc.bmj.com/content/34/Suppl_1/A421.2.full
SO  - Int J Gynecol Cancer2024 Mar 01; 34
AB  - Introduction/Background Clinical experience suggests that cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) play an important role in the management of ovarian cancer. In order to improve patient selection, the peritoneal surface disease severity score (PSDSS) was previously introduced for use in colorectal cancer patients. However, almost no data exist regarding the utility of the PSDSS index in ovarian cancer patients.Methodology A retrospective study of the effectiveness of CRS and HIPEC was carried out in 59 patients with ovarian cancer. The PSDSS was based on three criteria: symptoms, extent of peritoneal dissemination, and primary tumor structure as assessed by histology and biomarker expression. The PSDSS evaluation was performed in accordance with the original algorithm based on differentiating the ovarian cancer patients into two pathogenetic types depending on their histological and immunohistochemical results. The PSDSS stages scored from I to IV based scores for each of the three clinicopathological parameters (PSDSS Stage I: ≤ 3 points; PSDSS Stage II: 4–6 points; PSDSS Stage III: 7–10 points, and PSDSS Stage IV: ≥ 11 points).Results The overall survival time for patients with ovarian cancer in PSDSS Stage I was 48 ± 25.3 months. For PSDSS Stage II, the survival time was 26.5 ± 4.7 months. For PSDSS Stage III, it was 15.5 ± 4 months, and for PSDSS Stage IV, it was 6 ± 4.3 months. A multivariate analysis showed that the PSDSS stage was the only independent survival predictor.Conclusion These data demonstrate that a PSDSS based on two pathogenetic types may be useful for predicting survival outcomes in ovarian cancer patients treated with CRS/HIPEC.Disclosures The authors have no conflict of interest.Abstract 1298 Figure 1